Latest news with #MIBC
Business Standard
29-05-2025
- Business
- Business Standard
Deepak Nitrite rallies after Q4 PAT soars 106% QoQ to Rs 202 cr
Deepak Nitrite jumped 4.30% to Rs 2,086.25 after the company's consolidated net profit surged 106.35% to Rs 202.41 crore on 14.52% increase in revenue from operations to Rs 2,179.69 crore in Q4 FY25 over Q3 FY25. On year on year (YoY) basis, the companys consolidated revenue jumped 2.5%, while net profit declined 20.3% in Q4 FY25. Profit before tax (PBT) declined 20.2% YoY but increased 106% QoQ to Rs 278.71 crore in Q4 FY25. EBITDA stood at Rs 339 crore, up 6% YoY compared with Rs 320 crore posted in corresponding quarter last year. The EBITDA margin remained steady at 15% in Q4 FY25 compared to Q4 FY24. On segmental front, the revenue from advanced intermediates was at Rs 654 crore (down 3% YoY) while revenue from phenolics stood at Rs 1,532 crore, (up 5%) during the period under review. On full year basis, the companys consolidated net profit declined 14% to Rs 697.24 crore on 7.8% increase in revenue from operations to Rs 8,281.93 crore in FY25 over FY24. Deepak C. Mehta, chairman & managing director said: With all projects coming in with entire backward and forward integration we would be poised for much more resilient operations with an improved bottom line performance. In these turbulent times backward and forward integration go a longway in ensuring that ultimate consumers are taken care of and both the commodity and specialty businesses support each other. Our growth plan envisages development of further upstream products like Nitric Acid and downstream products such as MIBK, MIBC, for which capacities are set to be operationalized in the upcoming quarters. These will deepen the degree of integration across our business and strengthen our competitive position. The plan to manufacture polycarbonate resins is also taking more concrete shape and the Board of DCTL has recently approved investments for manufacturing 300 KTA of Phenol, 185 KTA of Acetone and 100 KTA of lsopropyl Alcohol (lPA) including greenfield infrastructure capex for an aggregate investment of about 3,500 crore. This is over and above the present manufacturing capacity of these products and the new capacity of Phenol and Acetone will be ultimately integrated to produce Polycarbonate Resins. This approval along with the previous approval of 5,000 crore of PC resins brings the aggregate investment pipeline for the PC Resin project to around 8,500 crore. As already mentioned, Deepak will be one of the largest single location producers of Phenol and Acetone in the entire world with more than half of the capacity converted into downstream derivatives such as Bisphenol A and PC Resins, etc. With the commitment to increased Research and Development Activity the new R&D Centre is scheduled to be operative during the year. We are already bringing forward new projects that would enhance our position in life sciences business as well as specialty solvents. New Products in the area of Material Sciences are also being considered based on core competencies of Deepak. Meanwhile, the companys board recommended a dividend of Rs 7.50 per share with a face value of Rs 2 per share for FY25, subject to approval of shareholders at ensuing annual general meeting (AGM. The dividend, if approved by shareholders at the ensuing 54th AGM of the company will be paid within 30 days from the date of AGM. Deepak Nitrite is a leading chemical intermediates producer with a diversified portfolio that caters to the dyes and pigments, agrochemical, pharmaceutical, plastics, textiles, paper and home and personal care segments. It also manufactures petrochemical-derived intermediates such as phenolics, acetone, and isopropyl alcohol (IPA) for both domestic and international markets.
Yahoo
15-02-2025
- Health
- Yahoo
ASCO GU｜RemeGen Announced Highly Encouraging Data from the Phase II Clinical Trial Evaluating Disitamab Vedotin plus Immunotherapy as Perioperative Regimen for Bladder Cancer
YANTAI, China, Feb. 15, 2025 /PRNewswire/ -- On the morning of February 14, 2025 (UTC-8), at the ongoing 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) held in San Francisco, USA, Professor Xinan Sheng from Peking University Cancer Hospital delivered the latest efficacy and safety data from the phase II clinical trial (NCT05297552, Study ID: RC48-C017) of Disitamab Vedotin (DV) in combination Toripalimab as the neoadjuvant therapy for HER2-expressing muscle-invasive bladder cancer (MIBC) in an oral presentation. This marks the first public disclosure of results from a prospective clinical study investigating an ADC drug in combination with an immunotherapy as a perioperative therapy for MIBC. The pathological complete response (pCR) rate reached an impressive 63.6%, which is a breakthrough improvement compared with traditional neoadjuvant chemotherapies (36%-42%). ASCO GU is one of the top urologic oncology conferences that leading experts worldwide in this field attend. The NCT05297552 study explored the synergy between the targeted therapy and immunotherapy in the perioperative setting for MIBC. Specifically, it assessed the safety and efficacy of the novel combination therapy featuring DV, a HER2-targeting ADC drug initially developed by RemeGen Co., Ltd. (RemeGen), and Toripalimab, a PD-1 inhibitor. In May 2024, based on the NCT05297552 study, the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) granted breakthrough therapy designation to DV. The preliminary results of this study were presented at the 2024 ASCO Annual Meeting and led to widespread attention and discussion among experts worldwide. The updated data at ASCO GU further validated the clinical benefits of this therapeutic approach. In the NCT05297552 study, 47 eligible patients (10.6% with HER2 IHC 1+, 57.4% with IHC 2+, and 31.9% with IHC 3+) received the investigational neoadjuvant therapy, among whom 33 patients underwent radical cystectomy and pelvic lymph node dissection (RC + PLND). As of the data cut-off date on December 3, 2024, the study demonstrated promising efficacy and manageable safety profiles: The pathological complete response (pCR) rate reached an impressive 63.6% (95% CI: 45.1% - 79.6%), nearly doubling that observed with traditional neoadjuvant chemotherapies (36%-42%). The pathological response rate was 75.8% (95% CI: 57.7% - 88.9%). The study showed that for patients with baseline clinical stage of T2N0, the postoperative pCR rate reached 85.7%. A pCR rate of 55.6% was also achieved in patients with other pathological subtypes of urothelial carcinoma at baseline. Patients benefited significantly regardless of PD-L1 positive/negative and regardless of HER2 expression status (IHC 1+/2+/3+), among whom the pCR rate stood at 84.6% for HER2 IHC 3+ patients. The 12-month event-free survival (EFS) rate of all patients who underwent radical cystectomy was 92.5%, and the 18-month EFS rate was 85.9%. The therapy exhibited a manageable safety profile. The incidence of grade 3 or higher treatment-emergent adverse events (TEAEs) was only 27.7%, notably lower than the traditional chemotherapy regimen (40%-50%), suggesting a favorable tolerability. RemeGen is advancing research on targeted and personalized therapies for bladder cancer through indication expansion and therapy innovation of DV, aiming to provide more potent treatment options for patients worldwide. Currently, studies are in-progress to explore the feasibility of expanding DV-based regimens from later-line to front-line treatment for locally advanced or metastatic urothelial cancer. There are also plans to broaden the research of DV as a neoadjuvant therapy for MIBC to the entire perioperative period and investigate the synergy between DV and chemotherapy or other immunotherapies in treating urothelial cancer. View original content to download multimedia: SOURCE RemeGen Co., Ltd Sign in to access your portfolio
